Cahu X.,University of Nantes |
Cahu X.,University of Rennes 1 |
Bodet-Milin C.,University of Nantes |
Brissot E.,University of Nantes |
And 15 more authors.
Annals of Oncology | Year: 2011
Background: In non-cutaneous T-cell/natural killer (T/NK) lymphomas, the prognostic value of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) during or after therapy is unknown. Patients and methods: In this retrospective study, 54 T/NK lymphoma patients were assessed using FDG-PET before (n = 40), during (n = 44) and/or after therapy (n = 31). Results: FDG-PET showed an abnormal FDG uptake in all cases. Interim FDG-PET was negative in 25 of 44 cases. After completion of therapy, 19 of 31 patients reached complete remission with negative FDG-PET. In ALK+ anaplastic large cell lymphomas, the 4-year progression-free survival (PFS) was 80% and the negative predictive value of posttherapy FDG-PET was 83% (n = 9). In ALK2 T/NK lymphomas, the 4-year PFS was 59% for patients with a negative interim FDG-PET versus 46% for patients with a positive interim FDG-PET (P = 0.28, n = 35). Similarly, there was no statistical difference in 4-year PFS between negative and positive post-therapy FDG-PET in these lymphomas (51% and 67%, respectively, P = 0.96). The 4-year cumulative incidence of relapse from a negative post-therapy FDG-PET was 53% in ALK2 T/NK lymphomas. Conclusions: Although T/NK lymphomas are FDG-avid at diagnosis, a negative interim or post-therapy FDG-PET does not translate into an improved PFS in ALK2 T/NK lymphomas. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. Source